Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Inhibikase Therapeutics (IKT) over the last 5 years, with Q3 2025 value amounting to $90.1 million.

  • Inhibikase Therapeutics' Shares Outstanding (Diluted Average) rose 91379.41% to $90.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 91379.41%. This contributed to the annual value of $23.7 million for FY2024, which is 29335.42% up from last year.
  • As of Q3 2025, Inhibikase Therapeutics' Shares Outstanding (Diluted Average) stood at $90.1 million, which was up 91379.41% from $90.0 million recorded in Q2 2025.
  • Inhibikase Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $90.1 million during Q3 2025, with a 5-year trough of $4.2 million in Q4 2022.
  • For the 5-year period, Inhibikase Therapeutics' Shares Outstanding (Diluted Average) averaged around $24.1 million, with its median value being $8.2 million (2024).
  • Per our database at Business Quant, Inhibikase Therapeutics' Shares Outstanding (Diluted Average) crashed by 8319.93% in 2022 and then surged by 131210.3% in 2025.
  • Quarter analysis of 5 years shows Inhibikase Therapeutics' Shares Outstanding (Diluted Average) stood at $18.2 million in 2021, then tumbled by 76.81% to $4.2 million in 2022, then surged by 42.74% to $6.0 million in 2023, then soared by 293.35% to $23.7 million in 2024, then soared by 279.77% to $90.1 million in 2025.
  • Its last three reported values are $90.1 million in Q3 2025, $90.0 million for Q2 2025, and $89.5 million during Q1 2025.